Medeor Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.medeortx.com
Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Terminated
- Conditions
- Immune Tolerance
- Interventions
- Drug: MDR product
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Medeor Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05010174
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants
Phase 2
Withdrawn
- Conditions
- Kidney Transplant Rejection
- Interventions
- Biological: MDR-103
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Medeor Therapeutics, Inc.
- Registration Number
- NCT03606746
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
Phase 2
Withdrawn
- Conditions
- Kidney Transplant Rejection
- Interventions
- Drug: Immunosuppressive AgentsBiological: MDR-102
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Medeor Therapeutics, Inc.
- Registration Number
- NCT03605654
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
Phase 3
Completed
- Conditions
- Kidney Transplant Rejection
- Interventions
- Biological: MDR-101
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Medeor Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03363945
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath